Intimation of Resignation of Chief Financial officer under regulation 30 of SEBI(LODR) Regulation 2015

CFO resignedCEO resignedKey managerial personnel resignedManagement Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹0.85

prior close

₹0.85

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+3.4% vs market

Pharmaceuticals peers, median of 146sector+0.5%+4.2% vs sector

On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+4.7

30m

+4.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7+1.3+3.4+0.5+4.2

Next day

+9.4+0.4+9.0-0.5+9.9

+15.3+0.3+15.0-0.8+16.1

+18.8+5.0+13.9+2.3+16.5

+20.0+6.7+13.3+2.9+17.1

+22.4+8.4+14.0+3.8+18.6

+25.9+10.3+15.6+4.8+21.0

15d

+27.1+12.8+14.2+7.3+19.8

+22.4+16.0+6.3+5.9+16.4

+24.7+16.9+7.8+8.3+16.4

+12.9+12.5+0.4+5.3+7.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 146Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mr. Altaf Hussain (DIN: 10351528) has resigned from his dual roles as Managing Director and Chief Financial Officer of Welcure Drugs & Pharmaceuticals Ltd, effective from the close of business hours on 5th May 2025. He cited personal reasons and other professional commitments as the reason for stepping down, and confirmed there are no other material reasons behind the exit. The Board has recorded its appreciation for his contributions during his tenure. No replacement for either role has been announced in this filing, and the intimation has been signed by Suraj Chagan Solanki, a Director on the board.

Likely market impact

Losing both the MD and CFO at the same time is a significant leadership vacuum for a small-cap pharmaceutical company and may concern shareholders about continuity in financial reporting and strategic execution. Investors should watch for a timely appointment of a new CFO and MD, as prolonged gaps could weigh on the stock price and signal governance weakness.